Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 06  •  04:00PM ET
2.10
Dollar change
-0.15
Percentage change
-6.67
%
Index- P/E- EPS (ttm)-0.07 Insider Own44.40% Shs Outstand47.13M Perf Week-6.67%
Market Cap98.97M Forward P/E- EPS next Y-1.38 Insider Trans0.00% Shs Float26.20M Perf Month-1.41%
Enterprise Value-78.23M PEG- EPS next Q-0.07 Inst Own46.66% Short Float0.80% Perf Quarter20.00%
Income-10.42M P/S4.58 EPS this Y88.35% Inst Trans-6.71% Short Ratio0.12 Perf Half Y28.05%
Sales21.60M P/B0.58 EPS next Y-400.61% ROA-7.38% Short Interest0.21M Perf YTD-33.44%
Book/sh3.65 P/C0.56 EPS next 5Y6.24% ROE-8.31% 52W High3.81 -44.91% Perf Year7.14%
Cash/sh3.76 P/FCF- EPS past 3/5Y42.52% 22.81% ROIC-6.05% 52W Low1.39 51.08% Perf 3Y-83.70%
Dividend Est.- EV/EBITDA- Sales past 3/5Y185.20% - Gross Margin89.03% Volatility8.63% 12.99% Perf 5Y-89.55%
Dividend TTM- EV/Sales-3.62 EPS Y/Y TTM97.60% Oper. Margin-461.62% ATR (14)0.24 Perf 10Y-
Dividend Ex-Date- Quick Ratio20.41 Sales Y/Y TTM-9.33% Profit Margin-48.24% RSI (14)46.02 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio20.41 EPS Q/Q-41.06% SMA20-8.46% Beta0.40 Target Price2.00
Payout- Debt/Eq0.00 Sales Q/Q-100.00% SMA501.35% Rel Volume0.24 Prev Close2.25
Employees40 LT Debt/Eq0.00 EarningsNov 06 BMO SMA2004.87% Avg Volume1.69M Price2.10
IPOAug 08, 2017 Option/ShortYes / Yes EPS/Sales Surpr.-489.81% - Trades Volume400,074 Change-6.67%
Date Action Analyst Rating Change Price Target Change
Aug-27-24Downgrade Piper Sandler Overweight → Neutral $5 → $1.75
Aug-21-24Downgrade TD Cowen Buy → Hold
Aug-21-24Downgrade Jefferies Buy → Hold $11 → $1.50
Dec-15-23Downgrade H.C. Wainwright Buy → Neutral
Jan-11-22Initiated Jefferies Buy $45
Oct-01-21Initiated Cowen Outperform
Sep-14-21Initiated Ladenburg Thalmann Buy $51
Sep-08-21Initiated Piper Sandler Overweight $45
Nov-06-25 08:00AM
Oct-24-25 12:30PM
Oct-17-25 09:45AM
Oct-16-25 08:30AM
Sep-02-25 08:00AM
05:32AM Loading…
Aug-12-25 05:32AM
Aug-07-25 08:00AM
Jul-22-25 08:00AM
Jun-19-25 08:00AM
Jun-13-25 08:44AM
May-28-25 08:00AM
May-21-25 08:00AM
May-08-25 04:05PM
Mar-26-25 08:00AM
Mar-19-25 11:52AM
08:00AM Loading…
Mar-14-25 08:00AM
Mar-04-25 04:05PM
Mar-03-25 08:00AM
Feb-24-25 08:00AM
Feb-18-25 08:00AM
Feb-05-25 04:05PM
Dec-21-24 06:31AM
Dec-19-24 06:30PM
Nov-06-24 08:00AM
Oct-30-24 04:05PM
Aug-20-24 05:00PM
Aug-07-24 08:00AM
Jul-31-24 04:05PM
Jul-05-24 01:07PM
May-29-24 04:05PM
05:30PM Loading…
May-23-24 05:30PM
May-09-24 01:52PM
May-08-24 12:53PM
08:00AM
May-01-24 08:01AM
Apr-09-24 08:00AM
Apr-03-24 09:40AM
Mar-18-24 09:40AM
Mar-17-24 08:00AM
Mar-15-24 10:43AM
Mar-13-24 09:05AM
08:00AM
Mar-06-24 08:00AM
Mar-05-24 04:30PM
Mar-01-24 04:08PM
Feb-26-24 04:05PM
Jan-26-24 04:05PM
Jan-19-24 04:05PM
Dec-15-23 09:14AM
Dec-14-23 04:05PM
Nov-08-23 08:46AM
08:00AM
Nov-06-23 04:05PM
Nov-01-23 04:05PM
Oct-19-23 04:05PM
Oct-12-23 04:05PM
Oct-05-23 04:05PM
Oct-03-23 04:05PM
Oct-02-23 08:00AM
Sep-20-23 04:30PM
Sep-05-23 08:00AM
Aug-09-23 08:00AM
Aug-02-23 08:00AM
May-25-23 05:30PM
May-23-23 08:00AM
May-10-23 08:00AM
May-03-23 08:00AM
Apr-26-23 04:05PM
Apr-14-23 01:00PM
Apr-06-23 04:30PM
Mar-28-23 08:00AM
Mar-27-23 08:00AM
Mar-26-23 02:00PM
Mar-15-23 08:00AM
Mar-03-23 08:00AM
Feb-22-23 08:00AM
Nov-17-22 08:00AM
Nov-09-22 08:00AM
Nov-08-22 04:00PM
Nov-03-22 08:00AM
Oct-27-22 08:00AM
Oct-12-22 08:01AM
08:00AM
Sep-22-22 04:01PM
Sep-01-22 08:00AM
Aug-10-22 08:00AM
Aug-04-22 06:21AM
Jul-28-22 08:30AM
Jun-23-22 08:00AM
Jun-01-22 08:00AM
May-31-22 08:00AM
May-26-22 05:10PM
May-18-22 07:00AM
May-12-22 08:32AM
07:00AM
May-09-22 08:00AM
May-04-22 08:00AM
Apr-28-22 05:07PM
Apr-18-22 08:00AM
Apr-08-22 01:09PM
Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Morristown, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BALL BRYANSee remarksMar 03 '25Sale2.352,1475,045102,853Mar 04 06:09 PM
Giacobello Scott M.CHIEF FINANCIAL OFFICERMar 03 '25Sale2.352,8066,59423,944Mar 03 08:38 PM
Lennon David JamesCHIEF EXECUTIVE OFFICERMar 03 '25Sale2.355,69013,37233,429Mar 03 08:37 PM
Lennon David JamesOfficerMar 03 '25Proposed Sale2.355,69013,372Mar 03 08:36 PM
Giacobello Scott M.OfficerMar 03 '25Proposed Sale2.352,8066,594Mar 03 08:34 PM
BALL BRYANOfficerMar 03 '25Proposed Sale2.352,1475,045Mar 03 08:31 PM